These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 19392871)

  • 1. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease.
    Lee ES; Kim N; Lee SH; Park YS; Kim JW; Jeong SH; Lee DH; Jung HC; Song IS
    Aliment Pharmacol Ther; 2009 Jul; 30(2):154-64. PubMed ID: 19392871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of and risk factors for erosive oesophagitis and non-erosive reflux disease: a nationwide multicentre prospective study in Korea.
    Kim N; Lee SW; Cho SI; Park CG; Yang CH; Kim HS; Rew JS; Moon JS; Kim S; Park SH; Jung HC; Chung IS;
    Aliment Pharmacol Ther; 2008 Jan; 27(2):173-85. PubMed ID: 17973646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus.
    Emerenziani S; Sifrim D; Habib FI; Ribolsi M; Guarino MP; Rizzi M; Caviglia R; Petitti T; Cicala M
    Gut; 2008 Apr; 57(4):443-7. PubMed ID: 17766596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of Nissen fundoplication in non-erosive and erosive gastro-oesophageal reflux disease.
    Broeders JA; Draaisma WA; Bredenoord AJ; Smout AJ; Broeders IA; Gooszen HG
    Br J Surg; 2010 Jun; 97(6):845-52. PubMed ID: 20473997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
    Sharma P; Johnson DA; Monyak JT; Illueca M
    Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of pre-endoscopy proton pump inhibitor use on the classification of non-erosive reflux disease and erosive oesophagitis.
    Gaddam S; Wani S; Ahmed H; Maddur P; Hall SB; Gupta N; Puli SR; Higbee A; Rastogi A; Bansal A; Sharma P
    Aliment Pharmacol Ther; 2010 Nov; 32(10):1266-74. PubMed ID: 20955446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton pump inhibitor therapy in gastro-oesophageal reflux disease decreases the oesophageal immune response but does not reduce the formation of DNA adducts.
    De Jonge PJ; Siersema PD; Van Breda SG; Van Zoest KP; Bac DJ; Leeuwenburgh I; Ouwendijk RJ; Van Dekken H; Kusters JG; Kuipers EJ
    Aliment Pharmacol Ther; 2008 Jul; 28(1):127-36. PubMed ID: 18384663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease.
    Wu JC; Lai LH; Chow DK; Wong GL; Sung JJ; Chan FK
    Neurogastroenterol Motil; 2011 Feb; 23(2):155-60, e31. PubMed ID: 21087355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.
    Miner PB
    Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():25-32. PubMed ID: 16483267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology, diagnosis and treatment of non-erosive reflux disease (NERD).
    Papa A; Urgesi R; Grillo A; Danese S; Guglielmo S; Roberto I; Fedeli G; Gasbarrini A; Gasbarrini G
    Minerva Gastroenterol Dietol; 2004 Sep; 50(3):215-26. PubMed ID: 15729197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis.
    Nakamura T; Shirakawa K; Masuyama H; Sugaya H; Hiraishi H; Terano A
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():19-26. PubMed ID: 15943842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis.
    Wu JC; Cheung CM; Wong VW; Sung JJ
    Clin Gastroenterol Hepatol; 2007 Jun; 5(6):690-5. PubMed ID: 17481961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors - a follow-up study of intraluminal-impedance guided therapy.
    Becker V; Bajbouj M; Waller K; Schmid RM; Meining A
    Aliment Pharmacol Ther; 2007 Nov; 26(10):1355-60. PubMed ID: 17900268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P; van Zanten SV; Mattsson H; Wernersson B
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring.
    Kohata Y; Fujiwara Y; Machida H; Okazaki H; Yamagami H; Tanigawa T; Watanabe K; Watanabe T; Tominaga K; Arakawa T
    J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():58-62. PubMed ID: 22486873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of gluten-free diet on preventing recurrence of gastroesophageal reflux disease-related symptoms in adult celiac patients with nonerosive reflux disease.
    Usai P; Manca R; Cuomo R; Lai MA; Russo L; Boi MF
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1368-72. PubMed ID: 18853995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized controlled trial: roxatidine vs omeprazole for non-erosive reflux disease.
    Nakamura K; Akiho H; Ochiai T; Motomura Y; Higuchi N; Okamoto R; Matsui N; Yasuda D; Akahoshi K; Kabemura T; Ihara E; Harada N; Ito T; Takayanagi R
    Hepatogastroenterology; 2010; 57(99-100):497-500. PubMed ID: 20698216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
    Miwa H; Sasaki M; Furuta T; Koike T; Habu Y; Ito M; Fujiwara Y; Wada T; Nagahara A; Hongo M; Chiba T; Kinoshita Y;
    Aliment Pharmacol Ther; 2007 Jul; 26(1):69-77. PubMed ID: 17555423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of gastro-oesophageal reflux disease without oesophagitis (NERD)--a reappraisal 10 years on.
    Pace F; Bollani S; Molteni P; Bianchi Porro G
    Dig Liver Dis; 2004 Feb; 36(2):111-5. PubMed ID: 15002817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
    Fass R; Chey WD; Zakko SF; Andhivarothai N; Palmer RN; Perez MC; Atkinson SN
    Aliment Pharmacol Ther; 2009 Jun; 29(12):1261-72. PubMed ID: 19392864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.